Managing type 1 diabetes can feel like a job that never clocks out. Glucose checks, alarms at night, and the constant math of food, stress, and insulin can grind people down. For many, modern pumps and sensors make life safer. Yet some still face sudden, severe lows that hit without warning. Those episodes can be terrifying, and they can turn ordinary routines into risk. That is why the phrase diabetes cure keeps resurfacing in recent research. It does not describe a magic switch that erases the disease forever. Instead, it points to something more specific: replacing the missing insulin-making cells, then proving they work inside a real human body.
A 2025 phase 1 to 2 trial in the New England Journal of Medicine tested zimislecel, a stem cell-derived islet cell therapy, in people with type 1 diabetes and severe hypoglycemia risk. The results suggested many could make insulin again, and some stopped using injected insulin for at least a year. An older 2024 report in Cell described a different approach in 1 person, using autologous chemically reprogrammed islets implanted in the abdomen. Together, these studies show why the word “cure” appears in headlines, and why the fine print still matters.
What does a diabetes cure mean for severe type 1 diabetes?
When people say diabetes cure, they often mean a clean break from the disease. For type 1 diabetes, that would require two achievements. Scientists would need to stop autoimmunity and rebuild beta cells permanently. No approved therapy can do that today. Research teams, therefore, use a narrower goal for high-risk patients. They aim for a functional diabetes cure. In practice, that means stable glucose without injected insulin. It also means freedom from severe hypoglycemia and emergency rescue. Some people may still use sensors and attend clinic visits. Some may take immune medicines that protect transplanted cells. Even with those ongoing needs, life can change if insulin independence lasts. They may also reduce long-term complications linked to high variability. Clinicians already use pancreas and islet transplants in selected cases.
Those procedures can deliver insulin independence, yet the organ supply is limited. They also require immune suppression, which many patients cannot accept. Cell-derived islets try to solve the supply problem. Severe hypoglycemia has a practical definition in trials. It includes episodes where another person must give carbohydrates, glucagon, or other help. The zimislecel trial focused on severe hypoglycemia because the benefit is clear. The investigators described the therapy in simple terms, writing, “Zimislecel is an allogeneic stem cell-derived islet-cell therapy.” Allogeneic means the cells come from a manufactured donor line. That supports scale, yet it can trigger immune rejection. The trial, therefore, paired the infusion with immunosuppressive drugs. To show real insulin production, the team measured C-peptide. C-peptide forms when the body makes insulin, not when insulin is injected. The researchers reported that C-peptide was undetectable at baseline in every participant.
After infusion, they detected C-peptide in all participants. That shift supports the engraftment and functioning of islet cells. However, the word cure still needs guardrails. A 1-year outcome cannot guarantee 10 years of protection. Immune suppression also changes the risk balance for many people. Even so, the study design shows why the phrase diabetes cure keeps appearing. It ties biology to real clinical events, not only to laboratory markers. The NEJM team also tied benefit to glycated hemoglobin, or HbA1c. HbA1c reflects average glucose over the prior 2 to 3 months. Lowering HbA1c can reduce microvascular complications over time. However, pushing HbA1c down can sometimes raise hypoglycemia risk. That trade-off makes this patient group important. If a therapy lowers HbA1c while also preventing severe lows, it addresses both sides.
The trial also tracked time in range using continuous glucose monitoring. That metric measures the daily percentage of time glucose stays between 70 and 180 mg per deciliter. Together, these endpoints help separate a short improvement from a meaningful shift. Even in the best scenario, people may still carry glucose tablets, wear a sensor, and attend transplant visits. Doctors will watch kidney function, blood pressure, infections, and drug levels. Researchers will also track antibodies and graft decline. If insulin returns, many recipients may still benefit from fewer dangerous lows and steadier sleep. Those practical gains explain the excitement. Yet durability will decide if it lasts.
How Zimislecel was tested and why the design matters
Trevor W. Reichman and colleagues designed the zimislecel study as a phase 1 to 2 trial. The PubMed record lists investigators at major transplant and diabetes centers. Sites included Toronto General Hospital, the University of Pennsylvania, and the University of Wisconsin. Other sites included Chicago, Pittsburgh, City of Hope, and KU Leuven, with work at Leiden and USC. Vertex Pharmaceuticals funded the work and employed several coauthors. That partnership reflects how complex cell therapies move from lab to clinic. Industry provides manufacturing and release testing. Academic centers provide transplant skills and intensive follow-up. The authors wrote, “We conducted a phase 1-2 study of zimislecel in persons with type 1 diabetes.”
They enrolled people whose severe hypoglycemia created a high clinical need. Many had limited awareness of falling glucose levels. That profile increases risk even with modern sensors and pumps. The trial, therefore, asked a direct question. Can new islet cells prevent dangerous lows while improving overall control? Zimislecel also builds on decades of islet transplantation experience. In conventional islet transplantation, doctors infuse donor islets into the liver. Some recipients reach insulin independence, yet donor supply stays scarce. The protocol included dose escalation and multiple parts. In part A, participants received a half dose, stated as 0.4 × 10^9 cells. The team infused the cells into the portal vein, which delivers blood to the liver.
Participants could receive a second half dose within 2 years. In parts B and C, participants received a full dose, stated as 0.8 × 10^9 cells. They received it as a single infusion. All participants also received glucocorticoid-free immunosuppressive therapy. That choice aimed to reduce steroid-driven hyperglycemia. The investigators used mixed meal tolerance testing to look for C-peptide. They wrote that the detection of serum C-peptide assessed engraftment and islet function. In part C, the primary endpoint combined safety with clear benefit. It required freedom from severe hypoglycemic events from days 90 through 365. It also required HbA1c below 7% or a drop of at least 1 percentage point. Secondary endpoints included safety and insulin independence between days 180 and 365. The abstract notes, “All the analyses were interim and not prespecified.” That line reminds readers that the numbers can shift with a longer follow-up.
Safety monitoring included blood counts, liver tests, and infection screening. Neutropenia risk influenced the follow-up schedule. The study also tracked time in range using continuous glucose monitoring. It defined the target range as 70 to 180 mg per deciliter. That metric can show fewer lows even when HbA1c looks unchanged. Clinicians also watched insulin doses and rescue carbohydrate use. These measures help connect lab markers to daily safety. Longer trials will clarify whether benefits persist fully after year one. They also tracked participant-reported outcomes, including fear of hypoglycemia and sleep disruption, because daily confidence matters. Investigators monitored liver blood flow and portal pressure during infusion to reduce clot risk. As longer follow-up arrives, teams will compare outcomes across sites and dosing schedules, refining who benefits most and who should avoid immunosuppression entirely.
What the NEJM results showed at 1 year
The interim analysis included 14 participants with at least 12 months of follow-up. Two participants received the half dose in part A. Twelve participants received the full dose in parts B and C. At baseline, every participant had undetectable C-peptide. That finding fits long-standing type 1 diabetes with minimal beta-cell function. After infusion, the authors reported engraftment in all participants. They wrote that islet function was present “as evidenced by the detection of C-peptide.” That phrase carries weight because injected insulin cannot create C-peptide. C-peptide also helps separate real graft function from changes in diet or insulin settings. The team used a 4-hour mixed meal test, which challenges the graft with glucose and amino acids. A working graft should respond during that test. In earlier islet transplants, some grafts fail quickly because of inflammation.
Seeing C-peptide in every participant suggests early survival and function. It also supports the idea that stem cell-derived islets can behave like donor islets. Clinical outcomes created the strongest case for a diabetes cure narrative. The abstract reports, “All 12 participants in parts B and C were free of severe hypoglycemic events.” It also says each had HbA1c below 7%. They spent more than 70% of their time in the range, defined as 70 to 180 mg per deciliter. That range matches common continuous glucose monitoring targets. For people with severe hypoglycemia, avoiding lows can conflict with tighter HbA1c goals. This trial suggests the graft supplied enough insulin to smooth both highs and lows. The headline number appears next. The authors wrote, “Ten of the 12 participants (83%) had insulin independence.”
They used no insulin on day 365. Insulin independence means no injected or pumped insulin. It does not mean freedom from clinic visits or prescriptions. Participants still took immunosuppressive drugs and completed frequent lab checks. Even so, a year without insulin can reduce daily burden and fear of sudden lows. Safety outcomes explain why researchers stay cautious. The abstract states, “Neutropenia was the most common serious adverse event, occurring in 3 participants.” Neutropenia lowers white blood cells and can raise infection risk. Two deaths occurred during follow-up. One death was caused by cryptococcal meningitis, an infection linked to immune suppression. The other death was linked to severe dementia with agitation, with progression of preexisting impairment. These events show that the price of insulin independence can be high. They also signal why future trials may refine immune regimens and screening.
Researchers must show that benefits outweigh risks across larger groups, not only in early volunteers. The study remained interim, so later data may change estimates. Still, the 1-year results provide a clear clinical signal. Durability will decide the label. Even with these promising numbers, clinicians will want to see stability across longer horizons, especially beyond 2 years. Graft function can fade as immune pressure builds or as islet mass slowly declines. Researchers will also examine whether insulin independence holds during infections, surgery, pregnancy, or other physiologic stress. Future reports should clarify quality of life changes, hospital admissions, and long-term complication trends.
What the 2024 cell transplant case adds
Zimislecel uses an allogeneic cell source, so recipients need immune suppression to avoid rejection. The 2024 Cell report explored an autologous approach, which starts with the patient’s own cells. Shusen Wang and colleagues reported 1-year results from a first-in-human phase I trial. They created islets using chemically induced pluripotent stem cells, often shortened to CiPSC islets. The summary says the trial assessed the feasibility of autologous CiPSC islet transplantation for type 1 diabetes. The authors placed the islets beneath the abdominal anterior rectus sheath. That site differs from classic islet transplantation, which commonly targets the liver. An abdominal site may allow imaging and biopsy with less risk. These practical features matter in early trials, where doctors want options if cells overgrow or fail. However, autologous does not automatically mean immune-free.
Type 1 diabetes begins with an autoimmune attack, and that attack can return. So, the approach may still require immune modulation in the future. The paper lists the registry number as ChiCTR2300072200. That registry detail signals formal oversight for a first-in-human effort. Chemical reprogramming aims to push adult cells back into a flexible state using small molecules. Teams then guide those cells into pancreatic lineages that resemble natural islets. Each patient batch still needs strict identity and purity testing. The clinical outcomes in this single patient were striking. The authors wrote, “The patient achieved sustained insulin independence starting 75 days post-transplantation.” They also reported improved time in the target glucose range. It increased from 43.18% at baseline to 96.21% by month 4 after transplantation.
The summary describes a fall in glycated hemoglobin to a non diabetic level. It later remained “around 5%” with time in target above 98%. The summary also states, “At 1 year, the clinical data met all study endpoints with no indication of transplant-related abnormalities.” Those phrases support feasibility and early safety in at least 1 case. Still, 1 patient cannot define average outcomes. It also cannot reveal rare harms, because rare harms need large numbers. Long-term safety also requires years of follow-up. Stem cell-derived products must avoid residual pluripotent cells that could grow unexpectedly. Researchers test identity and function before implantation. They also watch for imaging changes at the graft site. The report functions as a proof of concept and a blueprint for larger trials. The highlights note that transplantation to an abdominal site led to engraftment in this patient.
They also state that exogenous insulin-independent glycemic control was restored. Those statements connect the surgical site to the outcome. Future larger cohorts will show whether the same site works across different bodies and immune profiles. Durability beyond 1 year remains the critical test. A longer follow-up will also need to answer practical questions that a single success cannot resolve. For example, researchers must show that chemically reprogrammed islets remain stable and do not drift into unwanted cell types. They will also need to confirm that the abdominal implantation site maintains adequate oxygenation as the graft matures. Even if the cells are autologous, teams must watch for a returning autoimmune attack that could silently erode function over time.
What still stands between trials and a diabetes cure
These trials show that engineered islets can restore insulin production in humans. Turning that success into a broad diabetes cure still requires major work. The first barrier is immune risk. Allogeneic grafts face rejection, so recipients need immunosuppression. Immunosuppression increases infection risk and can alter cancer risk over time. It can also affect the kidneys, blood pressure, and lipid levels. The NEJM trial reported neutropenia and an opportunistic fungal infection death. Those signals will push teams to refine regimens and screening. Researchers also must address autoimmune memory in type 1 diabetes. Even autologous grafts may face renewed immune attack. Several groups are exploring gene-edited cells that resist immune recognition. Other groups are testing immune therapies that limit autoreactive T cells. Clinical proof for those add-ons remains limited, yet the direction is clear.
The safest cure would protect grafts without lifelong immune suppression. Patient selection will remain strict until safety improves. Many candidates have repeated severe lows despite optimized technology. Some already qualify for donor islet or pancreas transplantation. Cell-derived products could expand options when donor organs are unavailable. Yet clinicians will still weigh immunosuppression against the current quality of life. That calculus will differ for each person and each health system. The second barrier is durable delivery and manufacturing at scale. Portal vein infusion places islets in the liver, yet the liver can stress transplanted cells. Abdominal implantation may allow monitoring and removal, yet it must provide oxygen and blood supply. Researchers must show consistent function across different implant sites and body types.
Read More: New Diabetes Category Emerges: ‘Type 5’ Tied to Malnutrition
Manufacturing also must stay consistent across batches. Billions of cells must meet criteria for purity and potency. Even if insulin independence lasts, clinicians will monitor graft decline and antibody changes. Cost will shape access, because cell manufacturing is expensive. Health systems will ask whether emergency visits and complications fall over time. People considering trials should ask about infection prevention, vaccine planning, and early symptom reporting. The NEJM abstract ends with a careful summary. It states, “The results of this small, short-term study involving persons with type 1 diabetes support the hypothesis.” The authors said zimislecel can restore islet function. They called for further investigation. That sentence captures the present moment. A diabetes cure looks possible for severe cases, yet proof still needs more time. Future trials will likely include longer follow-up windows and prespecified analyses.
They may also compare outcomes to advanced pump systems and hybrid closed-loop algorithms. Researchers will track whether insulin independence persists through infections and stress. They will also measure kidney function, liver changes, and long-term infection rates. Only then can the cure language become routine in clinical guidelines. Researchers will also need to prove that these therapies work outside elite centers with deep transplant experience. That means standardizing surgical technique, lab monitoring, and infection prevention across many hospitals. Regulators will ask for clear plans to manage late complications, including malignancy screening and long-term immune suppression side effects. Payers will demand real-world evidence that costs fall through fewer emergencies, fewer admissions, and fewer complications over many years.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
A.I. Disclaimer: This article was created with AI assistance and edited by a human for accuracy and clarity.
Read More: Doctors Say Your Eyes Can Signal Diabetes and Cancer – Are You Watching?